1
|
Sotnikova EA, Kiseleva AV, Kutsenko VA, Zharikova AA, Ramensky VE, Divashuk MG, Vyatkin YV, Klimushina MV, Ershova AI, Revazyan KZ, Skirko OP, Zaicenoka M, Efimova IA, Pokrovskaya MS, Kopylova OV, Glechan AM, Shalnova SA, Meshkov AN, Drapkina OM. Identification of Pathogenic Variant Burden and Selection of Optimal Diagnostic Method Is a Way to Improve Carrier Screening for Autosomal Recessive Diseases. J Pers Med 2022; 12:jpm12071132. [PMID: 35887629 PMCID: PMC9322704 DOI: 10.3390/jpm12071132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 07/06/2022] [Accepted: 07/08/2022] [Indexed: 11/16/2022] Open
Abstract
Cystic fibrosis, phenylketonuria, alpha-1 antitrypsin deficiency, and sensorineural hearing loss are among the most common autosomal recessive diseases, which require carrier screening. The evaluation of population allele frequencies (AF) of pathogenic variants in genes associated with these conditions and the choice of the best genotyping method are the necessary steps toward development and practical implementation of carrier-screening programs. We performed custom panel genotyping of 3821 unrelated participants from two Russian population representative samples and three patient groups using real-time polymerase chain reaction (PCR) and next generation sequencing (NGS). The custom panel included 115 known pathogenic variants in the CFTR, PAH, SERPINA1, and GJB2 genes. Overall, 38 variants were detected. The comparison of genotyping platforms revealed the following advantages of real-time PCR: relatively low cost, simple genotyping data analysis, and easier detection of large indels, while NGS showed better accuracy of variants identification and capability for detection of additional pathogenic variants in adjacent regions. A total of 23 variants had significant differences in estimated AF comparing with non-Finnish Europeans from gnomAD. This study provides new AF data for variants associated with the studied disorders and the comparison of genotyping methods for carrier screening.
Collapse
Affiliation(s)
- Evgeniia A. Sotnikova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Anna V. Kiseleva
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- Correspondence:
| | - Vladimir A. Kutsenko
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, 1-73, Leninskie Gory, 119991 Moscow, Russia
| | - Anastasia A. Zharikova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 1-73, Leninskie Gory, 119991 Moscow, Russia
| | - Vasily E. Ramensky
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 1-73, Leninskie Gory, 119991 Moscow, Russia
| | - Mikhail G. Divashuk
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- All-Russia Research Institute of Agricultural Biotechnology, Timiryazevskaya Street, 42, 127550 Moscow, Russia
| | - Yuri V. Vyatkin
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
- Novosibirsk State University, 1, Pirogova Str., 630090 Novosibirsk, Russia
| | - Marina V. Klimushina
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Alexandra I. Ershova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Karina Z. Revazyan
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Olga P. Skirko
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Marija Zaicenoka
- Moscow Institute of Physics and Technology, Dolgoprudny, Institutskiy per.9, 141701 Dolgoprudny, Russia;
| | - Irina A. Efimova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Maria S. Pokrovskaya
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Oksana V. Kopylova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Anush M. Glechan
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Svetlana A. Shalnova
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Alexey N. Meshkov
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| | - Oxana M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per.10, Bld. 3, 101000 Moscow, Russia; (E.A.S.); (V.A.K.); (A.A.Z.); (V.E.R.); (M.G.D.); (Y.V.V.); (M.V.K.); (A.I.E.); (K.Z.R.); (O.P.S.); (I.A.E.); (M.S.P.); (O.V.K.); (A.M.G.); (S.A.S.); (A.N.M.); (O.M.D.)
| |
Collapse
|
2
|
Zyryanov SK, Ushkalova EA, Kondratyeva EI, Butranova OI, Kondakova YA. Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis. Biomedicines 2022; 10:biomedicines10051050. [PMID: 35625789 PMCID: PMC9139162 DOI: 10.3390/biomedicines10051050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/27/2022] [Accepted: 04/30/2022] [Indexed: 02/04/2023] Open
Abstract
(1) Background: Ciprofloxacin (CPF) is widely used for the treatment of cystic fibrosis, including pediatric patients, but its pharmacokinetics is poorly studied in this population. Optimal CPF dosing in pediatric patients may be affected by gene polymorphism of the enzymes involved in its biotransformation. (2) Materials and Methods: a two-center prospective non-randomized study of CPF pharmacokinetics with sequential enrollment of patients (n-33, mean age 9.03 years, male-33.36%), over a period from 2016 to 2021. All patients received tablets of the original CPF drug Cyprobay® at a dose of 16.5 mg/kg to 28.80 mg/kg. Blood sampling schedule: 0 (before taking the drug), 1.5 h; 3.0 h; 4.5 h; 6.0 h; 7.5 h after the first dosing. CPF serum concentrations were analyzed by high performance liquid chromatography mass spectrometry. The genotype of biotransformation enzymes was studied using total DNA isolated from whole blood leukocytes by the standard method. (4) Results: a possible relationship between the CA genotype of the CYP2C9 gene (c.1075A > C), the GG genotype of the CYP2D6*4 gene (1846G > A), the AG genotype of the GSTP1 gene (c.313A > G), the GCLC* genotype 7/7 and the CPF concentration in plasma (increased value of the area under the concentration−time curve) was established. Conclusions: Gene polymorphism of biotransformation enzymes may affect ciprofloxacin pharmacokinetics in children.
Collapse
Affiliation(s)
- Sergey K. Zyryanov
- Peoples’ Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russian Federation; (S.K.Z.); (E.A.U.)
- Department of Health of the City of Moscow, City Clinical Hospital No. 24, State Budgetary Institution of the City of Moscow, Pistzovaya Str. 10, 127015 Moscow, Russia
| | - Elena A. Ushkalova
- Peoples’ Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russian Federation; (S.K.Z.); (E.A.U.)
| | - Elena I. Kondratyeva
- Research Centre for Medical Genetics, 1 Moskvorechyie Str., 115522 Moscow, Russia;
| | - Olga I. Butranova
- Peoples’ Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russian Federation; (S.K.Z.); (E.A.U.)
- Correspondence: ; Tel.: +7-(903)-3767140
| | - Yulia A. Kondakova
- GBUZ NSO City Children’s Clinical Hospital of Emergency Medical Aid, Krasny Prospekt 3, 630007 Novosibirsk, Russia;
| |
Collapse
|
3
|
Kopylova OV, Ershova AI, Pokrovskaya MS, Meshkov AN, Efimova IA, Serebryanskaya ZZ, Blokhina AV, Borisova AL, Kondratskaya VA, Limonova AS, Smetnev SА, Skirko OP, Shalnova SА, Metelskaya VA, Kontsevaya AV, Drapkina OM. Population-nosological research biobank of the National Medical Research Center for Therapy and Preventive Medicine: analysis of biosamples, principles of collecting and storing information. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2022. [DOI: 10.15829/1728-8800-2021-3119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Aim. To analyze the structure of clinical data, as well as the principles of collecting and storing related data of the biobank of the National Medical Research Center for Therapy and Preventive Medicine (hereinafter Biobank).Material and methods. The analysis was carried out using the documentation available in the Biobank, as well as the databases used in its work. The paper presents clinical data on biosamples available in the Biobank as of August 18, 2021.Results. At the time of analysis, the Biobank had 373547 samples collected from 54192 patients within 37 research projects. The article presents the analysis of data representation and quantitative assessment of the presence/absence of common diagnoses in clinical projects. Approaches to documenting clinical information associated with biological samples stored in the Biobank were assessed. The methods and tools used for standardization and automation of processes used in the Biobank were substantiated.Conclusion. The Biobank of the National Medical Research Center for Therapy and Preventive Medicine is the largest research biobank in Russia, which meets all modern international requirements and is one of the key structures that improve the research quality and intensify their conduct both within the one center and in cooperation with other biobanks and scientific institutions. The collection and systematic storage of clinical abstracts of biological samples is an integral and most important part of the Biobank’s work.
Collapse
Affiliation(s)
- O. V. Kopylova
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. I. Ershova
- National Medical Research Center for Therapy and Preventive Medicine
| | - M. S. Pokrovskaya
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. N. Meshkov
- National Medical Research Center for Therapy and Preventive Medicine
| | - I. A. Efimova
- National Medical Research Center for Therapy and Preventive Medicine
| | | | - A. V. Blokhina
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. L. Borisova
- National Medical Research Center for Therapy and Preventive Medicine
| | | | - A. S. Limonova
- National Medical Research Center for Therapy and Preventive Medicine
| | - S. А. Smetnev
- National Medical Research Center for Therapy and Preventive Medicine
| | - O. P. Skirko
- National Medical Research Center for Therapy and Preventive Medicine
| | - S. А. Shalnova
- National Medical Research Center for Therapy and Preventive Medicine
| | - V. A. Metelskaya
- National Medical Research Center for Therapy and Preventive Medicine
| | | | - O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine
| |
Collapse
|
4
|
Boytsov SA, Drapkina OM, Shlyakhto EV, Konradi AO, Balanova YA, Zhernakova YV, Metelskaya VA, Oshchepkova EV, Rotar OP, Shalnova SA. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2021. [DOI: 10.15829/1728-8800-2021-3007] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The growing weight of noncommunicable diseases, primarily cardiovascular diseases (CVDs), is a great threat to the health of population worldwide, worsening the quality of life and reducing life expectancy. Realization of this threat led to initiation of epidemiological study by the Russian Ministry of Health to investigate the prevalence of CVDs and their risk factors, since it is CVDs that specify the high allcause mortality in Russia. In the modern history of epidemiology of non-infectious disease, the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study occupies a special place. This is the largest epidemiological study, which is considered as a continuation of preventive activity in order to obtain unbiased information on epidemiological characteristics of population in Russian regions. To conduct the study, the Research Organizing Committee of ESSE-RF study was created and a protocol was developed. All interested scientists and experts from following three centers took part in the work: National Medical Research Center for Therapy and Preventive Medicine, Almazov National Medical Research Center, National Medical Research Center of Cardiology. The Russian regions were justified and selected for participation. In 2012-2014 ESSE-RF study, 13 following Russian regions took part: Volgograd, Vologda, Voronezh, Ivanovo, Kemerovo, Tyumen Oblasts; Krasnoyarsk and Primorsky Krai; the Republic of North Ossetia (Alania); cities of Orenburg, Samara, St. Petersburg and Tomsk. All participated regions used a single study protocol, while biochemical parameters were determined in Federal centers using the same equipment and reagent kits. The paper presents some of the most interesting results that indicate a change in Russian epidemiological situation over the past few years. After the end of cross-sectional study, a field of priority research areas was formed in each center.Conclusion. Epidemiological studies are the most important scientific tool for assessing the prevalence of diseases, their risk factors, as well as predicting adverse events. Based on the results obtained, healthcare system and medical community determine priorities and develop related strategies (population-based and high-risk strategies). For their implementation, a regulatory and legal framework is being created.
Collapse
Affiliation(s)
| | - O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine
| | | | | | - Yu. A. Balanova
- National Medical Research Center for Therapy and Preventive Medicine
| | | | - V. A. Metelskaya
- National Medical Research Center for Therapy and Preventive Medicine
| | | | | | - S. A. Shalnova
- National Medical Research Center for Therapy and Preventive Medicine
| |
Collapse
|